ClinicalTrials.gg
Not yet recruitingNCT07556055Updated Apr 29, 2026

Etiology and Prognostic Factors in Patients With Acute Liver Failure

An observational study in Acute Liver Failure, sponsored by Li-Ying Sun. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Li-Ying Sun · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
400
Sex
All
01

Study summary

Acute liver failure (ALF) is a rare but life-threatening condition with high mortality. Despite advances in supportive care and liver transplantation, prognosis varies significantly across etiologies, particularly in patients with indeterminate causes.

This study aims to investigate the dynamic changes of clinical and biochemical indicators, identify potential etiologies-especially in indeterminate ALF-and evaluate prognostic risk factors. A dynamic prediction model will be developed to optimize clinical decision-making, including liver transplantation timing.

Both retrospective and prospective cohorts will be included. Multi-omics analyses (including transcriptomics, proteomics, metabolomics, and metagenomic sequencing) will be performed on liver tissue and biological samples to explore disease mechanisms and etiology.

02

Conditions studied

  • Acute Liver Failure

Browse trials for

03

In context

Liver Failure, Acute

96 studies on the registry are indexed under Liver Failure, Acute; 20 are open to participants now.

This study's planned enrollment of 400 is above the median of 112 across 34 observational studies indexed under Liver Failure, Acute.

Browse Liver Failure, Acute studies →

Lead sponsor

This is the only study on the registry with Li-Ying Sun as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients diagnosed with acute liver failure who are treated at Beijing Friendship Hospital, Capital Medical University. Both adult and pediatric patients meeting established diagnostic criteria for acute liver failure will be included.

The study includes two cohorts: a retrospective cohort of patients treated between November 2016 and February 2026, and a prospective cohort of newly diagnosed patients enrolled from March 2026 onward.

Patients will be followed longitudinally to evaluate clinical outcomes, including survival, liver transplantation, and transplant-free survival.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients meeting diagnostic criteria for acute liver failure:

Adults: Acute onset without pre-existing liver disease, development of hepatic encephalopathy ≥ grade II within 4 weeks Pediatrics: Acute onset (\<26 weeks), no chronic liver disease, coagulopathy not corrected by vitamin K: ≥1.5 with encephalopathy OR; INR >2 regardless of encephalopathy

  • Patients (or guardians) who provide

Exclusion criteria

Exclusion Criteria:

  • Presence of end-stage extrahepatic disease without effective treatment
  • Pregnant or breastfeeding women
  • Inability or unwillingness to provide or comply with study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
400 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Liver transplantation
  • Spontaneous survival
  • Death
06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3)

  2. Transplant-Free Survival

    Time frame: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3)

  3. Liver Transplantation Rate

    Time frame: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3

Secondary outcomes

  1. Etiologic features identified by multi-omics analysis

    Etiologic features in participants with acute liver failure will be assessed through multi-omics analyses of biospecimens, including liver tissue obtained from resected diseased liver during surgery (approximately 3 cm³) or from one ultrasound-guided liver biopsy core (approximately 2 cm in length), together with blood, urine, and stool samples. Multi-omics testing includes transcriptomic sequencing, proteomic analysis, metabolomic analysis, and metagenomic sequencing.

    Time frame: From enrollment to completion of biospecimen collection and etiologic multi-omics assessment, up to 7 days

  2. Short-Term Mortality

    Time frame: 90 days after enrollment

  3. Development of Prognostic Prediction Model

    A prognostic model will be developed using clinical variables, laboratory parameters, and dynamic changes over time. Multivariable logistic regression and receiver operating characteristic (ROC) curve analysis will be used to evaluate model performance, including discrimination and calibration.

    Time frame: Up to 3 years after enrollment

  4. Change in alanine aminotransferase (ALT) over time

    Serial serum ALT measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  5. Change in aspartate aminotransferase (AST) over time

    Serial serum AST measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  6. Change in total bilirubin over time

    Serial total bilirubin measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  7. Change in international normalized ratio (INR) over time

    Serial INR measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  8. Change in prothrombin time (PT) over time

    Serial PT measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  9. Change in serum creatinine over time

    Serial serum creatinine measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  10. Change in C-reactive protein (CRP) over time

    Serial serum C-reactive protein measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  11. Change in direct bilirubin over time

    Serial direct bilirubin measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  12. Change in prothrombin activity (PTA) over time

    Serial prothrombin activity (PTA) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  13. Change in blood ammonia over time

    Serial blood ammonia measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  14. Change in blood phosphorus over time

    Serial blood phosphorus measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  15. Change in white blood cell count (WBC) over time

    Serial white blood cell count (WBC) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  16. Change in red blood cell count (RBC) over time

    Serial red blood cell count (RBC) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  17. Change in hemoglobin (HGB) over time

    Serial hemoglobin (HGB) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  18. Change in platelet count (PLT) over time

    Serial platelet count (PLT) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  19. Change in D-dimer over time

    Serial D-dimer measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  20. Change in serum albumin over time

    Serial serum albumin measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  21. Change in arterial lactate over time

    Serial arterial lactate measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  22. Change in blood glucose over time

    Serial blood glucose measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  23. Change in arterial pH over time

    Serial arterial pH measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  24. Change in CD4+ T-cell count over time

    Serial CD4+ T-cell count measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  25. Change in CD8+ T-cell count over time

    Serial CD8+ T-cell count measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  26. Change in CD19+ B-cell count over time

    Serial CD19+ B-cell count measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  27. Change in CD56+ natural killer cell count over time

    Serial CD56+ natural killer cell count measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  28. Change in CD4+/CD8+ ratio over time

    Serial CD4+/CD8+ ratio measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  29. Change in immunoglobulin M (IgM) over time

    Serial serum immunoglobulin M (IgM) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  30. Change in immunoglobulin G (IgG) over time

    Serial serum immunoglobulin G (IgG) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  31. Change in immunoglobulin A (IgA) over time

    Serial serum immunoglobulin A (IgA) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  32. Change in complement C3 over time

    Serial serum complement C3 measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

  33. Change in complement C4 over time

    Serial serum complement C4 measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.

    Time frame: Every 48 hours from admission to discharge, assessed up to 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2036, 129 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 29, 2026
StartEst.
Mar 30, 2026
Primary completionEst.
Dec 31, 2036
CompletionEst.
Dec 31, 2037
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556055
Lead sponsor
Li-Ying Sun
Responsible party
Li-Ying Sun (Director of Department of Critical Liver Diseases, Beijing Friendship Hospital) — Sponsor-investigator
First posted
Apr 29, 2026
Start date
Mar 30, 2026 (estimated)
Primary completion
Dec 31, 2036 (estimated)
Completion
Dec 31, 2037 (estimated)
Last update
Apr 29, 2026

Study contacts

Wan-Ting Zhang, MD
Contact
13699189579@163.com
+86 13699189579

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion